Market Newsdesk

San Clemente, CA, May 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global WholeHealth Partners Corp (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains breakthrough on rising neurological disease and receives its first purchase order from Nunzia Pharmaceutical after the agreement was signed last month. 

“This is the first of many Purchase Orders to Global as Nunzia plans on expansion,” stated Michael Mitsunaga, President of Nunzia Pharmaceutical Inc.

“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo. “Nunzia Pharmaceutical with nutraceutical for anxiety and stress based on their patented formulas and their pharmaceutical drug they are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests,” says Mr. Strongo. “With the new tests for Alzheimer’s, Parkinson’s and Dementia, Global is right in the path of success.”  

The marketing and sales partnership with Nunzia Pharmaceutical with 8k filing dated 04/19/2021, gives Global the ability to sell the AstraZeneca Vaccine and the Johnson & Johnson vaccine and other products of Nunzia including their patented nutraceutical for stress and anxiety and soon FDA approved drug for ASD (Autistic Spectrum of Disorders), including Autism, ADD, ADHD, Fragile X, and PTSD. The Nunzia Nutraceutical aids in Nutritional deficiencies and therefore helps people.

Nutritional deficiencies. Not drinking enough liquids (dehydration); not getting enough thiamin (vitamin B-1), which is common in people with chronic alcoholism; and not getting enough vitamins B-6 and B-12 in your diet can cause dementia-like symptoms. Copper and vitamin E deficiencies also can cause dementia symptoms.

https://www.mayoclinic.org/diseases-conditions/dementia/symptoms-causes/syc-20352013

Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, “The Company’s goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.”

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.

Media Contact:

Name: Charles Strongo,

CEO, Global WholeHealth Partners Corp.

Email: [email protected]

Phone for Sales: (949) 757-4152

www.gwhpcorp.com

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

DALLAS, May 05, 2021 (GLOBE NEWSWIRE) — Blucora, Inc. (NASDAQ: BCOR), a leading provider of technology-enabled, tax focused financial solutions, today announced financial results for the first quarter ended March 31, 2021.

First Quarter Highlights and Recent Developments

• Increased total revenue for the quarter to $278.4 million, or 6% year-over-year
• GAAP Net Income of $27.6 million, or $0.56 per diluted share
• Non-GAAP Net Income of $51.0 million, or $1.04 per diluted share
• Total client assets ended the quarter up 39% year over year to $84.8 billion, with $36.8 billion, or 43.4% in advisory assets
• Advisory assets increased 56% year-over-year, including the addition of approximately $5.0 billion in Avantax Planning Partners (“APP”) assets
• Free cash flow of $45.1 million in Q1 2021 vs. $39.1 million during Q1 2020, or a 15% increase
• Strong cash position, ending the quarter with $191.8 million in cash and cash equivalents compared to $150.1 million at December 31, 2020, while reducing net debt levels since December 31, 2020 with a 3.5x net leverage ratio as of March 31, 2021
• Announced appointment of Tina Perry, President of OWN, to our Board of Directors

“As we continue to serve our financial professionals and assist in the growth of their businesses, our wealth management segment reported strong results with the first quarter coming in at the high end of our expectations, commented Chris Walters, Blucora’s President and Chief Executive Officer. “We continue to see growth in total client assets as well as advisory assets, which sets the Company up for a strong year.”

Tax Season Update

“Our progress leading up to the conclusion of the extended Tax Year 2020 continues to be on track. We are realizing the benefits of continued strong NPS scores, retention rates, improved marketing effectiveness and ARPU strength driven by our broad set of customer offerings for consumers.” Walters continued.

Summary Financial Performance: Q1 2021

($ in millions except per share amounts)

	Q1 2021				Q1 2020				Change
Revenue:
Wealth Management	$	154.5			$	145.0			7		%
Tax Software	$	123.9			$	118.3			5		%
Total Revenue	$	278.4			$	263.3			6		%
Segment Operating Income
Wealth Management	$	19.4			$	22.6			(14	)	%
Tax Software	$	50.9			$	37.8			35		%
Total Segment Operating Income	$	70.3			$	60.4			16		%
Unallocated Corporate-Level General and Administrative Expenses	$	(5.7	)		$	(7.0	)		19		%
GAAP:
Operating Income (Loss)	$	37.2			$	(241.8	)		115		%
Net Income (Loss)	$	27.6			$	(315.5	)		109		%
Diluted Net Income (Loss) Per Share	$	0.56			$	(6.60	)		108		%
Non-GAAP: (1)
Adjusted EBITDA	$	64.6			$	53.3			21		%
Net Income	$	51.0			$	43.6			17		%
Diluted Net Income per Share	$	1.04			$	0.90			16		%

(1)	See reconciliations of all non-GAAP to GAAP measures presented in this release in the tables below.

Second Quarter and Full Year 2021 Outlook

($ in millions except per share amounts)	2Q 2021	Full Year 2021
Wealth Management Revenue	$155.5 – $161.5	$631.5 – $649.5
TaxAct Revenue	$82.5 – $87.5	$212.5 – $218.0
Total Revenue	$238.0 – $249.0	$844.0 – $867.5
Wealth Management Segment Operating Income	$17.5 – $19.5	$79.0 – $83.5
TaxAct Segment Operating Income	$53.0 – $58.0	$72.0 – $76.5
Unallocated Corporate-Level General and Administrative Expenses	$7.5 – $7.0	$28.5 – $27.5
GAAP:
Net Income	$22.5 – $31.5	($12.5) – $2.0
Net Income per share	$0.45 – $0.63	($0.25) – $0.04
Non-GAAP:
Adjusted EBITDA (1)	$63.0 – $70.5	$122.5 – $132.5
Non-GAAP Net Income (1)	$47.0 – $55.5	$67.5 – $80.0
Non-GAAP Net Income per share (1)	$0.94 – $1.11	$1.34 – $1.60

(1)	See reconciliations of all non-GAAP to GAAP measures presented in this release in the tables below.

Conference Call and Webcast

A conference call and live webcast will be held today at 8:30 a.m. Eastern Time during which the Company will further discuss first quarter results, its outlook for full year 2021, its tax season update, and other business matters. We will also provide supplemental financial information to our results on the Investor Relations section of the Blucora corporate website at www.blucora.com prior to the call. The supplemental financial information has also been furnished with the SEC on Form 8-K. A replay of the call will be available on our website.

About Blucora®

Blucora, Inc. (NASDAQ: BCOR) is on the forefront of financial technology, a provider of data and technology-driven solutions that empowers people to improve their financial wellness. Blucora operates in two segments including (i) wealth management, through its Avantax Wealth Management brand, with a collective $85 billion in total client assets as of March 31, 2021 and (ii) tax software, through its TaxAct business, a market leader in tax software with approximately 3 million consumer and 23,000 professional users in 2020. With integrated tax-focused software and wealth management, Blucora is uniquely positioned to assist our customers in achieving better long-term outcomes via holistic, tax-advantaged solutions. For more information on Blucora, visit www.blucora.com.

Source: Blucora

Blucora Investor Relations
Dee Littrell (972) 870-6463
[email protected]

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “believes,” “estimates,” “should,” “could,” “would,” “plans,” “expects,” “intends,” “anticipates,” “may,” “forecasts,” “future,” “will,” “projects,” “predicts,” “potential,” “continues,” “target,” “outlook” and similar expressions and variations. Actual results may differ significantly from management’s expectations due to various risks and uncertainties including, but not limited to: the impact of the coronavirus pandemic on our results of operations and our business, including the impact of the resulting economic and market disruption, the extension of tax filing deadlines and other related relief; our ability to effectively implement our future business plans and growth strategy; our ability to effectively compete within our industry; our ability to attract and retain financial professionals, qualified employees, clients, and customers, as well as our ability to provide strong customer/client service; our ability to close, finance, and realize all of the anticipated benefits of acquisitions, as well as our ability to integrate the operations of recently acquired businesses, and the potential impact of such acquisitions on our existing indebtedness and leverage; our future capital requirements and the availability of financing, if necessary; our ability to meet our current and future debt service obligations, including our ability to maintain compliance with our debt covenants; downgrade of the Company’s credit ratings; our ability to generate strong performance for our clients and the impact of the financial markets on our clients’ portfolios; the impact of new or changing legislation and regulations (or interpretations thereof) on our business, including our ability to successfully address and comply with such legislation and regulations (or interpretations thereof) and increased costs, reductions of revenue, and potential fines, penalties or disgorgement to which we may be subject as a result thereof; risks, burdens, and costs, including fines, penalties or disgorgement, associated with our business being subjected to regulatory inquiries, investigations or initiatives; risks associated with legal proceedings, including litigation and regulatory proceedings; our ability to manage leadership and employee transitions, including costs and time burdens on management and our board of directors related thereto; political and economic conditions and events that directly or indirectly impact the wealth management and tax software industries; our ability to respond to rapid technological changes, including our ability to successfully release new products and services or improve upon existing products and services; the compromising of confidentiality, availability or integrity of information, including cyberattacks; our expectations concerning the revenues we generate from fees associated with the financial products that we distribute; risks related to goodwill and other intangible asset impairment; our ability to develop, establish, and maintain strong brands; risks associated with the use and implementation of information technology and the effect of security breaches, computer viruses, and computer hacking attacks; our ability to comply with laws and regulations regarding privacy and protection of user data; our ability to maintain our relationships with third-party partners, providers, suppliers, vendors, distributors, contractors, financial institutions, industry associations, and licensing partners, and our expectations regarding and reliance on the products, tools, platforms, systems, and services provided by these third parties; our beliefs and expectations regarding the seasonality of our business; our assessments and estimates that determine our effective tax rate; and our ability to protect our intellectual property and the impact of any claim that we have infringed on the intellectual property rights of others. A more detailed description of these and certain other factors that could affect actual results is included in the Company’s filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.

Blucora, Inc.

Condensed Consolidated Statements of Operations

(Unaudited) (Amounts in thousands, except per share data)

	Three months ended March 31,
	2021				2020
Revenues:
Wealth management services revenue	$	154,491			$	144,989
Tax software services revenue	123,892				118,331
Total revenue	278,383				263,320
Operating expenses:
Cost of revenue:
Wealth management services cost of revenue	108,623				102,342
Tax software services cost of revenue	5,578				4,013
Total cost of revenue	114,201				106,355
Engineering and technology	7,128				8,515
Sales and marketing	77,562				79,710
General and administrative	24,685				24,728
Acquisition and integration	8,103				5,682
Depreciation	2,300				1,796
Amortization of other acquired intangible assets	7,175				7,748
Impairment of goodwill	—				270,625
Total operating expenses	241,154				505,159
Operating income (loss)	37,229				(241,839		)
Other loss, net (1)	(7,883		)		(6,135		)
Income (loss) before income taxes	29,346				(247,974		)
Income tax expense	(1,700		)		(67,520		)
Net income (loss)	$	27,646			$	(315,494	)
Net income (loss) per share:
Basic	$	0.57			$	(6.60	)
Diluted	$	0.56			$	(6.60	)
Weighted average shares outstanding:
Basic	48,261				47,827
Diluted	49,097				47,827

(1)	Other loss, net consisted of the following (in thousands):

	Three months ended March 31,
	2021				2020
Interest expense	$	7,183			$	5,316
Amortization of debt issuance costs	363				313
Accretion of debt discounts	277				68
Total interest expense	7,823				5,697
Interest income	(2		)		(14		)
Other	62				452
Other loss, net	$	7,883			$	6,135

Blucora, Inc.

Condensed Consolidated Balance Sheets

(Unaudited) (Amounts in thousands)

	March 31, 2021				December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents	$	191,803			$	150,125
Cash segregated under federal or other regulations	2,241				637
Accounts receivable, net of allowance	24,348				12,736
Commissions and advisory fees receivable	26,021				26,132
Other receivables	186				717
Prepaid expenses and other current assets, net	12,015				10,321
Total current assets	256,614				200,668
Long-term assets:
Property and equipment, net	64,160				58,500
Right-of-use assets, net	22,886				23,455
Goodwill, net	454,821				454,821
Other intangible assets, net	315,294				322,179
Other long-term assets	5,342				4,569
Total long-term assets	862,503				863,524
Total assets	$	1,119,117			$	1,064,192
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	22,019			$	9,290
Commissions and advisory fees payable	18,762				19,021
Accrued expenses and other current liabilities	72,735				56,419
Deferred revenue—current	5,280				12,298
Lease liabilities—current	3,327				2,304
Current portion of long-term debt, net	1,786				1,784
Total current liabilities	123,909				101,116
Long-term liabilities:
Long-term debt, net	552,684				552,553
Deferred tax liability, net	30,394				30,663
Deferred revenue—long-term	6,015				6,247
Lease liabilities—long-term	35,723				36,404
Other long-term liabilities	25,738				24,919
Total long-term liabilities	650,554				650,786
Total liabilities	774,463				751,902
Stockholders’ equity:
Common stock, par $0.0001—900,000 authorized shares; 49,615 shares issued and 48,309 shares outstanding at March 31, 2021; 49,483 shares issued and 48,177 shares outstanding at December 31, 2020	5				5
Additional paid-in capital	1,602,948				1,598,230
Accumulated deficit	(1,229,900		)		(1,257,546		)
Treasury stock, at cost—1,306 shares at March 31, 2021 and December 31, 2020	(28,399		)		(28,399		)
Total stockholders’ equity	344,654				312,290
Total liabilities and stockholders’ equity	$	1,119,117			$	1,064,192

Blucora, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited) (Amounts in thousands)

	Three months ended March 31,
	2021				2020
Operating activities:
Net income (loss)	$	27,646			$	(315,494	)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Stock-based compensation	5,610				(1,201		)
Depreciation and amortization of acquired intangible assets	10,418				10,168
Impairment of goodwill	—				270,625
Reduction of right-of-use lease assets	569				1,625
Deferred income taxes	(269		)		57,898
Amortization of debt issuance costs	363				313
Accretion of debt discounts	277				68
Change in fair value of acquisition-related contingent consideration	6,300				—
Accretion of lease liability	514				424
Other	(78		)		495
Cash provided (used) by changes in operating assets and liabilities:
Accounts receivable	(11,541		)		(9,066		)
Commissions and advisory fees receivable	111				3,457
Other receivables	531				(3,239		)
Prepaid expenses and other current assets	(1,694		)		(1,715		)
Other long-term assets	(828		)		2,560
Accounts payable	12,729				17,744
Commissions and advisory fees payable	(259		)		(1,965		)
Lease liabilities	(172		)		(1,289		)
Deferred revenue	(7,250		)		(7,820		)
Accrued expenses and other current and long-term liabilities	10,745				23,276
Net cash provided by operating activities	53,722				46,864
Investing activities:
Purchases of property and equipment	(8,598		)		(7,715		)
Asset acquisitions	(587		)		—
Net cash used by investing activities	(9,185		)		(7,715		)
Financing activities:
Proceeds from credit facilities	—				55,000
Payments on credit facilities	(453		)		(10,313		)
Proceeds from stock option exercises	63				—
Tax payments from shares withheld for equity awards	(865		)		(918		)
Net cash provided (used) by financing activities	(1,255		)		43,769
Net increase in cash, cash equivalents, and restricted cash	43,282				82,918
Cash, cash equivalents, and restricted cash, beginning of period	150,762				86,450
Cash, cash equivalents, and restricted cash, end of period	$	194,044			$	169,368

Blucora, Inc.

Segment Information

(Unaudited) (Amounts in thousands)

	Three months ended March 31,
	2021				2020
Revenue:
Wealth Management (1)	$	154,491			$	144,989
Tax Software (1)	123,892				118,331
Total revenue	278,383				263,320
Operating income (loss):
Wealth Management	19,396				22,598
Tax Software	50,888				37,753
Corporate-level activity (2)	(33,055		)		(302,190		)
Total operating income (loss)	37,229				(241,839		)
Other loss, net	(7,883		)		(6,135		)
Income (loss) before income taxes	29,346				(247,974		)
Income tax expense	(1,700		)		(67,520		)
Net income (loss)	$	27,646			$	(315,494	)

(1)	Revenues by major category within each segment are presented below (in thousands):

	Three months ended March 31,
	2021			2020
Wealth Management:
Advisory	$	91,119		$	78,757
Commission	52,534			50,580
Asset-based	5,329			10,579
Transaction and fee	5,509			5,073
Total Wealth Management revenue	$	154,491		$	144,989
Tax Software:
Consumer	$	110,567		$	103,821
Professional	13,325			14,510
Total Tax Software revenue	$	123,892		$	118,331

(2)	Corporate-level activity included the following (in thousands):

	Three months ended March 31,
	2021			2020
Unallocated corporate-level general and administrative expenses	$	5,694		$	7,016
Stock-based compensation	5,610			(1,201		)
Acquisition and integration costs	8,103			5,682
Depreciation	3,243			2,420
Amortization of acquired intangible assets	7,175			7,748
Impairment of goodwill	—			270,625
Executive transition costs	—			9,184
Headquarters relocation costs	—			716
Contested proxy and other legal and consulting costs	3,230			—
Total corporate-level activity	$	33,055		$	302,190

Blucora, Inc.

Reconciliations of Non-GAAP Financial Measures to the Nearest Comparable GAAP Measures (1)

Adjusted EBITDA Reconciliation (1)

(Unaudited) (Amounts in thousands)

	Three months ended March 31,
	2021			2020
Net income (loss) (2)	$	27,646		$	(315,494	)
Stock-based compensation	5,610			(1,201		)
Depreciation and amortization of acquired intangible assets	10,418			10,168
Other loss, net	7,883			6,135
Acquisition and integration—Excl. Change in fair value of acquisition-related contingent consideration	1,803			5,682
Acquisition and integration—Change in fair value of acquisition-related contingent consideration	6,300			—
Impairment of goodwill	—			270,625
Executive transition costs	—			9,184
Headquarter relocation costs	—			716
Contested proxy and other legal and consulting costs	3,230			—
Income tax expense	1,700			67,520
Adjusted EBITDA (1)	$	64,590		$	53,335

Non-GAAP Net Income and Non-GAAP Net Income Per Share Reconciliation (1)

(Unaudited) (Amounts in thousands, except per share amounts)

	Three months ended March 31,
	2021				2020
Net income (loss) (2)	$	27,646			$	(315,494	)
Stock-based compensation	5,610				(1,201		)
Amortization of acquired intangible assets	7,175				7,748
Acquisition and integration—Excluding change in fair value of HKFS Contingent Consideration	1,803				5,682
Acquisition and integration—Change in fair value of HKFS Contingent Consideration	6,300				—
Impairment of goodwill	—				270,625
Executive transition costs	—				9,184
Headquarters relocation costs	—				716
Contested proxy and other legal and consulting costs	3,230				—
Cash tax impact of adjustments to GAAP net income	(543		)		(736		)
Non-cash income tax (benefit) expense	(269		)		67,037
Non-GAAP net income	$	50,952			$	43,561
Per diluted share:
Net income (loss) (2) (3)	$	0.56			$	(6.54	)
Stock-based compensation	0.11				(0.02		)
Amortization of acquired intangible assets	0.15				0.16
Acquisition and integration—Excluding change in fair value of HKFS Contingent Consideration	0.04				0.12
Acquisition and integration—Change in fair value of HKFS Contingent Consideration	0.13				—
Impairment of goodwill	—				5.61
Executive transition costs	—				0.19
Headquarters relocation costs	—				0.01
Contested proxy and other legal and consulting costs	0.07				—
Cash tax impact of adjustments to GAAP net income	(0.01		)		(0.02		)
Non-cash income tax (benefit) expense	(0.01		)		1.39
Non-GAAP net income per share	$	1.04			$	0.90
Weighted average shares outstanding used in computing per diluted share amounts	49,097				48,253

Net Leverage Ratio Reconciliation (4) (5)

(Amounts in thousands)

	March 31, 2021					December 31, 2020
Debt:
Senior secured credit facility	$	562,703				$	563,156
Cash:
Cash and cash equivalents	$	191,803				$	150,125
Net debt (6)	$	370,900				$	413,031
Trailing twelve months:
Wealth Management segment operating income	$	68,993				$	72,195
Tax Software segment operating income	62,756					49,621
	$	131,749				$	121,816
Unallocated corporate-level general and administrative expenses	(25,367		)			(26,689		)
Adjusted EBITDA (1)	$	106,382				$	95,127
Net leverage ratio (4) (5)	3.5			x		4.3			x

Trailing Twelve Month Adjusted EBITDA Reconciliation (1) (4)

(Amounts in thousands)

	For the trailing twelve months ended
	March 31, 2021				December 31, 2020
Net income (loss) (2)	$	385			$	(342,755	)
Stock-based compensation	16,877				10,066
Depreciation and amortization of acquired intangible assets	40,157				39,907
Other loss, net	33,052				31,304
Acquisition and integration—Excluding change in fair value of HKFS Contingent Consideration	18,906				22,785
Acquisition and integration—Change in fair value of HKFS Contingent Consideration	14,600				8,300
Executive transition costs	1,517				10,701
Headquarter relocation costs	1,147				1,863
Contested proxy and other legal and consulting costs	3,230				—
Income tax (benefit) expense	(23,489		)		42,331
Impairment of goodwill and an intangible asset	—				270,625
Adjusted EBITDA (1)	$	106,382			$	95,127

Operating Free Cash Flow Reconciliation (7)

(Amounts in thousands)

	Three months ended March 31,
	2021				2020
Net cash provided by operating activities (8)	$	53,722			$	46,864
Purchase of property and equipment (8)	(8,598		)		(7,715		)
Operating free cash flow (7)	$	45,124			$	39,149

Adjusted EBITDA Reconciliation for Forward-Looking Guidance (1)

(Amounts in thousands)

	Ranges for the three months ending						Ranges for the year ending
	June 30, 2021						December 31, 2021
	Low			High			Low				High
Net income (loss)	$	22,500		$	31,500		$	(12,500	)		$	2,000
Stock-based compensation	5,500			5,400			21,500				21,200
Depreciation and amortization of acquired intangible assets	11,100			10,800			45,000				44,500
Other loss, net	8,800			8,500			33,500				32,400
Acquisition, integration, and contested proxy and other legal and consulting costs (9)	12,900			12,300			32,800				31,000
Income tax expense	2,200			2,000			2,200				1,400
Adjusted EBITDA	$	63,000		$	70,500		$	122,500			$	132,500

Non-GAAP Net Income and Non-GAAP Net Income Per Share Reconciliation

for Forward-Looking Guidance (1)

(Amounts in thousands, except per share amounts)

	Ranges for the three months ending								Ranges for the year ending
	June 30, 2021								December 31, 2021
	Low				High				Low				High
Net income (loss)	$	22,500			$	31,500			$	(12,500	)		$	2,000
Stock-based compensation	5,500				5,400				21,500				21,200
Amortization of acquired intangible assets	7,200				7,100				28,600				28,300
Acquisition, integration, and contested proxy and other legal and consulting costs (9)	12,900				12,300				32,800				31,000
Cash tax impact of adjustments to net loss	(500		)		(400		)		(2,000		)		(1,700		)
Non-cash income tax benefit	(600		)		(400		)		(900		)		(800		)
Non-GAAP net income	$	47,000			$	55,500			$	67,500			$	80,000
Per diluted share:
Net income (loss) (3)	$	0.45			$	0.63			$	(0.25	)		$	0.04
Stock-based compensation	0.11				0.11				0.43				0.42
Amortization of acquired intangible assets	0.14				0.14				0.57				0.57
Acquisition, integration, and contested proxy and other legal and consulting costs (9)	0.26				0.25				0.65				0.62
Cash tax impact of adjustments to net loss	(0.01		)		(0.01		)		(0.04		)		(0.03		)
Non-cash income tax benefit	(0.01		)		(0.01		)		(0.02		)		(0.02		)
Non-GAAP net income per share	$	0.94			$	1.11			$	1.34			$	1.60
Weighted average shares outstanding used in computing per diluted share amounts	50,100				50,000				50,300				50,100

Notes to Reconciliations of Non-GAAP Financial Measures to the Nearest Comparable GAAP Measure

(1)	We define Adjusted EBITDA as net income (loss), determined in accordance with GAAP, excluding the effects of stock-based compensation, depreciation and amortization of acquired intangible assets, other loss, net, acquisition and integration costs, impairment of goodwill and an intangible asset, executive transition costs, headquarters relocation costs, contested proxy and other legal and consulting costs, and income tax expense. Other loss, net primarily constitutes our interest expense, net of interest income. Acquisition and integration costs primarily relate to the acquisition of HKFS and the acquisition of 1st Global. Impairment of goodwill relates to the impairment of our Wealth Management reporting unit goodwill in the first quarter of 2020. The impairment of an intangible asset relates to the impairment of the HD Vest trade name intangible asset in the third quarter of 2019. Executive transition costs relate to the departure of certain Company executives in the first quarter of 2020. Headquarters relocation costs relate to the process of moving from our Dallas and Irving offices to our new headquarters. We believe that Adjusted EBITDA provides meaningful supplemental information regarding our performance. We use this non-GAAP financial measure for internal management and compensation purposes, when publicly providing guidance on possible future results, and as a means to evaluate period-to-period comparisons. We believe that Adjusted EBITDA is a common measure used by investors and analysts to evaluate our performance, that it provides a more complete understanding of the results of operations and trends affecting our business when viewed together with GAAP results, and that management and investors benefit from referring to this non-GAAP financial measure. Items excluded from Adjusted EBITDA are significant and necessary components to the operations of our business and, therefore, Adjusted EBITDA should be considered as a supplement to, and not as a substitute for or superior to, GAAP net income (loss). Other companies may calculate Adjusted EBITDA differently and, therefore, our Adjusted EBITDA may not be comparable to similarly titled measures of other companies. We define non-GAAP net income as net income (loss), determined in accordance with GAAP, excluding the effects of stock-based compensation, amortization of acquired intangible assets, acquisition and integration costs, impairment of goodwill, executive transition costs, headquarters relocation costs, contested proxy and other legal and consulting costs, non-capitalized debt issuance expense, the related cash tax impact of those adjustments, and non-cash income tax (benefit) expense. We exclude the non-cash portion of income tax expense because of our ability to offset a substantial portion of our cash tax liabilities by using deferred tax assets, which primarily consist of U.S. federal net operating losses. The majority of these net operating losses will either be utilized or expire between 2021 and 2024. Non-capitalized debt issuance expense relates to the expense recognized as a result of the increase to our term loan in the third quarter of 2020. We believe that non-GAAP net income and non-GAAP net income per share provide meaningful supplemental information to management, investors, and analysts regarding our performance and the valuation of our business by excluding items in the statement of operations that we do not consider part of our ongoing operations or have not been, or are not expected to be, settled in cash. Additionally, we believe that non-GAAP net income and non-GAAP net income per share are common measures used by investors and analysts to evaluate our performance and the valuation of our business. Non-GAAP net income and non-GAAP net income per share should be evaluated in light of our financial results prepared in accordance with GAAP and should be considered as a supplement to, and not as a substitute for or superior to, GAAP net income (loss) and net income (loss) per share. Other companies may calculate non-GAAP net income and non-GAAP net income per share differently, and, therefore, our non-GAAP net income and non-GAAP net income per share may not be comparable to similarly titled measures of other companies.
(2)	As presented in the condensed consolidated statements of operations (unaudited).
(3)	Any difference in the “per diluted share” amounts between this table and the condensed consolidated statements of comprehensive income is due to using different weighted average shares outstanding in the event that there is GAAP net loss but non-GAAP net income and vice versa.
(4)	Non-GAAP measure using Adjusted EBITDA for the last twelve months. Adjusted EBITDA for the trailing twelve month period is reconciled to the nearest GAAP measure on page 10.
(5)	Net leverage ratio is calculated by dividing net debt by Adjusted EBITDA for the trailing twelve months.
(6)	We define net debt, a non-GAAP financial measure, as cash and cash equivalents less the outstanding principal of debt. Management believes that the presentation of this non-GAAP financial measure provides useful information to investors because it is an important liquidity measurement that reflects our ability to service our debt.
(7)	We define operating free cash flow, which is a non-GAAP measure, as net cash provided by (used in) operating activities less purchases of property and equipment. We believe operating free cash flow is an important liquidity measure that reflects the cash generated by our businesses, after the purchases of property and equipment, that can then be used for, among other things, strategic acquisitions and investments in the businesses, stock repurchases, and funding ongoing operations.
(8)	As presented in the condensed consolidated statements of cash flows (unaudited).
(9)	The breakout of components cannot be determined on a forward-looking basis without unreasonable efforts.

ROUYN-NORANDA, Quebec, May 05, 2021 (GLOBE NEWSWIRE) — Radisson Mining Resources Inc. (TSX-V: RDS, OTC: RMRDF): (“Radisson” or the “Company”) is pleased to announce significant high-grade gold intercepts from the ongoing 130,000 m exploration drill program at its 100% owned O’Brien gold project located along the Larder-Lake-Cadillac Break (see location map 1 and location map 2), halfway between Rouyn-Noranda and Val-d’Or in Quebec, Canada.

Key highlights

• Notable intercepts from expansion drilling at depth along high-grade trend #2,
  • OB-21-185:
    • 14.94 g/t Au over 1.60 m, including 36.80 g/t over 0.60 m
  • OB-21-187:
    • 8.87 g/t over 5.00 m, including 14.15 g/t over 2.00 m
  • OB-21-191
    • 5.09 g/t Au over 6.10 m including 11.75 g/t over 1.00 m
  • OB-21-193:
    • 18.87 g/t Au over 2.10 m including 43.80 g/t over 0.90 m
  • OB-21-201:
    • 11.13 g/t Au over 10.70 m including 13.90 g/t over 8.20 m
  • Visible gold was observed in OB-21-187, OB-21-191 and OB-21-201
• Drill results thus far have traced high-grade gold mineralization down to 800 m vertical depth in this sector where the majority of currently defined resources are within a vertical depth of 400 m from surface.
• Results continue to demonstrate continuity of mineralization below 400 m, within an area measuring approximately 400 m vertically and up to a minimum of 120 m laterally.
• Several relatively broad high grade intercepts from holes OB-21-187, OB-21-191, OB-21-201, OB-20-124 (8.35 g/t Au over 6.00 m), OB-20-180 (18.42 g/t over 5.00 m), OB-20-156 (11.32 g/t Au over 11.80 m) and OB-20-156W2 (5.77 g/t over 7.10 m) suggest potential for wider mineralized zones (well in excess of average widths of approx. 2.90 m in the current resource), between 400 – 700 m vertical depth, where multiple veins are interpreted to intersect each other.
• 130,000 m drill program (commenced Aug 2019) underway at O’Brien.
  • 79,776 m completed thus far with results pending for 13,760 m
• Cash balance of approx. $12.5 M

Highlight drill results

Hole	Zone	From (m)	To (m)	Core Length (m)	Au (g/t) – Uncut	Comments
OB-20-183	Trend #2
		425.10	427.10	2.00	5.29	North Mafic Volcanic
	Including	425.10	426.10	1.00	10.55
OB-21-185	Trend #2
		763.40	765.00	1.60	14.94	South Porphyry
	Including	763.40	764.00	0.60	36.80
OB-21-187	Trend #2
		704.70	709.70	5.00	8.87	South Mafic Volcanic*VG
	Including	705.70	707.70	2.00	14.15
OB-21-191	Trend #2
		744.90	751.00	6.10	5.09	South Mafic Volcanic
	Including	746.00	747.00	1.00	11.75
	AND	764.00	766.60	2.60	5.43	South Porphyry*VG
	Including	764.80	765.70	0.90	10.60
OB-21-193	Trend #2
		573.40	575.50	2.10	18.87	South Mafic Volcanic*VG
	Including	573.40	574.30	0.90	43.80
OB-21-201	Trend #2
		502.30	513.00	10.70	11.13	South Mafic Volcanic*VG
	Including	502.30	510.50	8.20	13.90
	Which Includes	505.00	508.00	3.00	19.20

1. VG denotes the presence of visible gold
2. Core length or down hole width. True widths are estimated at 70% to 80% of down hole width. To the extent possible, primary intercepts reflect minimum mining width (1.5 m true width) consistent with assumptions used in the 2019 resource estimate.
3. Assay grades shown uncapped. A capping factor of 60 g/t Au was used in the 2019 resource estimate
4. Table includes only intercepts that meet 5 g/t Au cut-off and minimum mining width constraints used in the 2019 MRE. For a full listing of drill results from current drilling program click here.

“Drill results continue to increase our confidence in the robust grade and scale potential at the O’Brien Project. Results thus far suggest the potential to double the depth extent of resources in each trend, while also expanding mineralization laterally to the east and west. We are particularly impressed by several broad intercepts along trend #2 that highlight the potential for wider mineralized zones created by the intersection of multiple mineralized veins, between 400 m and 700 m from surface. Observed mineralized widths in these areas appear to be meaningfully higher than the average 2.90 m in currently modeled resource areas, in turn significantly enhancing the high-grade nature of the deposit.

“While the majority of our work program has been focused within 1 km along strike to the east of the historic O’Brien Mine, we believe there is significantly more upside to be unlocked from a prospective land package that includes more than 5 km of strike length along the prolific Cadillac Break. We look forward to a steady stream of news flow as we step out systematically further along strike and deeper beyond the limits of drilling to date, including high-potential targets to the west of the old O’Brien Mine,” commented Rahul Paul, President and Interim Chief Executive Officer.

Step-out drilling highlights resource growth potential up to 330 m below current resources in trend #2 (600 m east of the old O’Brien Mine)

OB-21-183 (5.29 g/t over 2.00 m), OB-21-185 (14.94 g/t over 1.60 m), OB-21-187 (8.87 g/t over 5.00 m), OB-21-191 (5.09 g/t over 6.10 m), OB-21-193 (18.87 g/t over 2.10 m) and OB-21-201 (13.90 g/t over 8.20 m) demonstrate continuity of high-grade mineralization at depth along high-grade trend #2.

Newly released intercepts and previously released intercepts from holes have now traced mineralization down to a vertical depth of 800 m, in this sector where the majority of defined resources are within 400 m from surface. These results also appear to align nicely with an historical intercept of 17.46 g/t over 1.00 m (KW-04-02W1) obtained further down-plunge at a depth of approximately 1,100 m (refer Figure 2 and 3).

Several relatively broader intercepts from holes OB-21-187, OB-21-191, OB-21-201, OB-20-124 (8.35 g/t Au over 6.00 m), OB-20-180 (18.42 g/t over 5.00 m), OB-20-156 (11.32 g/t Au over 11.80 m) and OB-20-156W2 (5.77 g/t over 7.10 m) suggest potential for wider mineralized zones (5 – 20 m wide) between 400 – 700 m vertical depth, likely highlighting the impact of cross-cutting high-grade mineralized veins.

Mineralization in trend #2 is currently open for expansion below 800 m as well as laterally to the east and west. Drilling is currently ongoing in this sector with additional results expected in the coming weeks.

Drilling at O’Brien continues to validate the litho-structural model while highlighting resource growth potential laterally and at depth

Drilling to date has continued to define and expand three high-grade mineralized trends, located approximately 300 m, 600 m and 900 m respectively to the east of the old O’Brien Mine. Mineralized trends identified bear similarities with structures previously mined at O’Brien down to a depth of 1,100 m (historical production of 587 koz grading 15.25 g/t).

Drilling so far has demonstrated continuity of mineralization well below the boundary of defined resources in all three trends, which remain open for expansion laterally and at depth. In trend #1, drilling has highlighted continuity of mineralization down to a vertical depth of 950 m, while current resources are mostly limited to a vertical depth of approximately 600 m. In trend #2, drilling has highlighted continuity of mineralization down to a vertical depth of over 800 m, while current resources are mostly within 400 m from surface. In trend #3, drilling has traced mineralization down to 500 m vertical depth from surface. Current resources are mostly confined to within a vertical depth of 240 m.

Almost all drilling conducted as part of the ongoing campaign has been within a strike length of approximately 1 km to the east of the old O’Brien mine, representing only a small portion of more than 5.2 km of prospective strike that Radisson controls along the Cadillac Break. Given current geological understanding, the ongoing validation of the litho structural model, the company estimates there is strong exploration for additional high-grade gold trends along the whole 5.2 km prospective land package on the prolific Larder-Lake Cadillac Break.

79,776
m of drilling completed to date with assays pending for approx. 13,760 m

This release represents approximately 5,260 m of drilling in 9 drill holes. Released results to date (since the commencement of drilling in August 2019) represent approximately 45% of the 130,000 m envisioned to be completed by the end of 2021. As of April 30, 2021, the company remains well funded with approximately $12.5 m in cash.

Reallocation of responsibilities related to exploration and technical services

As part of a reorganization of the team, Radisson is pleased to announce that Donald Trudel (previously Senior Project Geologist for O’Brien) has been promoted Exploration Manager for Radisson Mining, while Nicolas Guivarch has been promoted to Senior Geologist – Technical Services (previously Exploration Manager). As Exploration Manager for the Company, Mr. Trudel will be entrusted with oversight of day-to-day operational and administrative activities related to Exploration. In his capacity as Senior Geologist – Technical Services, Mr. Guivarch will be responsible for oversight of Technical Services activities for the Company including geological modeling and database management.

Mr. Trudel and Mr. Guivarch will continue to work closely with Ken Williamson who, in his capacity as Senior Advisor, Geology, will continue to play a broader supervisory role with the exploration group, overseeing both the Exploration and Technical Services functions.

Figure 1. Au Grade distribution: OB-21-183, OB-21-185, OB-21-187, OB-21-191, OB-21-193 and OB-21-201

Figure 2. O’Brien Gold Project: Resource Block Model @ 5.00 g/t cut-off; Longitudinal section looking North

Figure 3. O’Brien Gold Project: Cross section – Mineralized trend #2

Figure 4. Visible gold in OB-21-187, OB-21-191 and OB-21-201

QA/QC

All drill cores in this campaign are NQ in size. Assays were completed on sawn half-cores, with the second half kept for future reference. The samples were analyzed using standard fire assay procedures with Atomic Absorption (AA) finish at ALS Laboratory Ltd, in Val-d’Or, Quebec. Samples yielding a grade higher than 5 g/t Au were analyzed a second time by fire assay with gravimetric finish at the same laboratory. Samples containing visible gold were analyzed with metallic sieve procedure. Standard reference materials, blank samples and duplicates were inserted prior to shipment for quality assurance and quality control (QA/QC) program.

Qualified Person

Kenneth Williamson, M.Sc., P.Geo., Senior Advisor, Geology and Nicolas Guivarch, M. Sc., P.Geo., Senior Geologist – Technical Services are the qualified persons pursuant to the requirements of NI 43-101, and have reviewed and approved the technical disclosure in this press release.

Radisson mining resources Inc.

Radisson is a gold exploration company focused on its 100% owned O’Brien project, located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Quebec. The Bousquet-Cadillac mining camp has produced over 21,000,000 ounces of gold over the last 100 years. The project hosts the former O’Brien Mine, considered to have been the Quebec’s highest-grade gold producer during its production (1,197,147 metric tons at 15.25 g/t Au for 587,121 ounces of gold from 1926 to 1957; Kenneth Williamson 3DGeo-Solution, July 2019). For more information on Radisson, visit our website at www.radissonmining.com or contact:

On behalf of the board of directors

Rahul Paul
President and Interim CEO

For more information on Radisson, visit our website at www.radissonmining.com or contact:

Hubert Parent-Bouchard
Chief Financial Officer
819-763-9969
[email protected]

Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to, those relating to the intended use of proceeds of the Offering, the development of the O’Brien project and generally, the above “About Radisson Mining Resources Inc.” paragraph which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws, and are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements and future events, could differ materially from those anticipated in such statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Radisson’s disclosure documents on the SEDAR website at


www.sedar.com


.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s endeavours to develop the O’Brien project and, more generally, its expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

• More than half of patients with genetic diseases remain undiagnosed, even after performing Exome and Genome Sequencing
• By performing deep genetic analyses and Bio/Databank mining, CENTOGENE discovers six novel gene-disease associations and evidence supporting 31 candidate genes
• Study reveals value of such Bio/Databanks in diagnosing and accelerating treatment options for rare disease patients

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2021 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today research revealing six novel gene-disease associations for a wide range of genetic disorders and confirmation of 31 additional candidate genes. The findings are a result of in-depth analyses into the Company’s rare disease Bio/Databank, after standard genetic testing was unable to determine the exact cause of symptoms. As a result, over 90 patients were able to finally receive a diagnosis – opening the potential to diagnose countless others following further research. Additionally, these findings have revealed potential treatment options for patients based on known-disease overlaps.

The landmark study’s findings have been published in Genetics in Medicine (https://www.nature.com/articles/s41436-021-01159-0) – the official Journal of the American College of Medical Genetics and Genomics.

Prof. Peter Bauer, Chief Genomic Officer at CENTOGENE, said, “There are more than 7,000 rare diseases that are known to date, and our research shows that there are even more to be identified. We see it as our responsibility to dive deeper into patient information when carrying out genetic testing. In this case, we were able to provide patients with a diagnosis with diseases that were not previously on anyone’s radar. Even more, we were able to help improve their quality of life – opening up treatment and management options.”

“Although technological advancements over the past decade have led to improved diagnostics, our study shows that simply applying a genetic test is not enough,” adds Dr. Aida Bertoli-Avella, Head of Research Data Analysis. “Especially when it comes to rare diseases, you have to look past the surface – using advanced tools to reveal the underlying cause of a disease and open up a new world of treatment options.”

The research led to over 90 patients receiving a diagnosis based on the six new revealed rare diseases and 31 candidate genes – gaining access to future treatment options and improved medical management.

About the Study

While technology has advanced over the past ten years, more than half of patients with genetic diseases remain undiagnosed, even after applying genome-wide diagnostic approaches. The challenge of variant interpretation remains at the forefront of diagnostic challenges, in part due to the missing gene-phenotype link.

Leveraging CENTOGENE’s rare disease Bio/Databank, the Company carried out an extensive Exome Sequencing and Genome Sequencing evaluation of genes with no known disease association and patients suffering genetic diseases that had remained undiagnosed. From there, the Company performed analyses on its biobank using specific criteria, which enabled further identification of unrelated patients displaying similar phenotypes. Ultimately, this led to the discovery of six novel gene-disease associations based on 38 severely affected patients with variants in six genes: BLOC1S1, IPO8, MMP15, PLK1, RAP1GDS1, and ZNF699, as well as the elucidation of 31 additional candidate genes.

To read the complete study in Genetics in Medicine, visit: https://www.nature.com/articles/s41436-021- 01159-0

About CENTOGENE

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.9 billion weighted data points from approximately 600,000 patients representing over 120 different countries as of December 31, 2020.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of December 31, 2020, the Company collaborated with over 30 pharmaceutical partners.

Important Notice and Disclaimer

This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities, and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties, and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on April 15, 2021, and other current reports and documents furnished to or filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Media Contact:

CENTOGENE
Ben Legg
Corporate Communications
[email protected]

FTI Consulting
Bridie Lawlor O’Boyle
+1.917.929.5684
[email protected]